cas 1449598-86-0|| where to buy 2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Nombre del producto:2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

IUPAC Name:2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Unidad de embalaje	Stock disponible	Precio($)
CM337294-1g	in stock	ǜƎǜ
CM337294-10g	in stock	ũțțǶ
CM337294-100g	in stock	ưȬưǶ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1449598-86-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1449598-86-0; Fórmula molecular:C8H4ClFN2O; Punto de fusión:-; Código de sonrisas:O=C1C=C(Cl)N=C2N1C=C(F)C=C2; Densidad:

: Número de catálogo:CM337294; Peso molecular:198.58; Punto de ebullición:; Nº Mdl:MFCD28659052; Almacenamiento:

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.